NEW YORK (GenomeWeb News) - Ensemble Discovery said today it has struck a collaboration with Roche to develop a test that may be used to analyze combinations of specific receptors that may be used to help select cancer patients that are most likely to respond to particular therapies.
Under the agreement, the companies will use Ensemble’s DNA Programmed Chemistry technology to study combinations of epidermal growth factor receptors that are found in some cancer tissues.
Ensemble said the goal of the project is to develop a test that will correlate EGFR dimer patterns with the efficacy of certain anti-cancer drugs in an effort to improve therapy selection.
The company noted that the EGFR family includes commonly targeted cancer-related molecules, and added that there are six cancer drugs on the market targeted against this family and “several more in clinical trials.”
Ensemble’s senior VP and biodetection chief David Livingston said the collaboration with Roche will offer the company “a unique opportunity to apply the collective expertise and experience for the development of our tests in cancer diagnosis."